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F igure 3.1 Diagram of the arterial 
circulation at the base of the brain 
(Adapted from Gray H . Anatomy of the 
Human Body, 1918. F igure 519) 
 
3 IN T R O DU C T I O N 
 
Subarachnoid hemorrhage (SAH) is bleeding into the subarachnoid space surrounding the 
brain. SAH may occur spontaneously, or following traumatic brain injury. Spontaneous SAH 
is in 85% of cases caused by rupture of an intracranial aneurysm. This is called aneurysmal 
SAH (aSAH). An intracranial aneurysm is a disorder involving localized dilation of an 
intracranial artery. About 95% of intracranial aneurysms are saccular outpouchings of the 
arterial wall. The remaining aneurysms are either mycotic or fusiform widening of an artery. 
Saccular aneurysms are located at the major bifurcations of large intracranial arteries, either in 
the anterior cerebral artery, internal carotid artery, middle cerebral artery or basilar artery. A 
diagram of the arterial circulation at the base of the brain is shown in Figure 3.1. Non-
aneurysmal spontaneous SAH is usually 
perimesencephalic hemorrhage, or less frequently due 
to arteriovenous malformations, cerebral neoplasms, 
arterial inflammation, or venous thrombosis.1 
 
3.1 Diagnosis and treatment of aSA H 
SAH is suspected in patients with sudden onset of 
severe headache, which may be followed by 
confusion, focal neurological deficits, or loss of 
consciousness. The diagnosis of SAH is confirmed by 
detection of blood in the subarachnoid space on non 
contrast-enhanced computed tomogram of the brain 
or through lumbar puncture. Cerebral angiography is 
then performed to determine the presence of an 
intracranial aneurysm, either through endovascular 
catheter angiography (digital subtraction 
angiography) or computed tomography angiography.1 
In Norway, the government is responsible for 
hospital services through state ownership of regional 
health authorities. Patients with verified aSAH are usually accepted for immediate admission 
into one of the five public neurosurgical centers (Haukeland University Hospital in Bergen, St 
Olavs Hospital in Trondheim, Ullevål and Rikshospitalet in Oslo, and the University Hospital 
of North Norway in Tromsø). The treatment for aSAH is exclusion of the aneurysm from the 
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circulation through endovascular embolization or microsurgery.2 The case fatality of aSAH is 
50%, with 20% of surviving patients remaining dependent on help for activities of daily 
living.3 Non-aneurysmal, perimesencephalic SAH does not require invasive treatment and the 
patients have a normal life expectancy.4 
 
3.2 Incidence of aSA H  
The incidence of aSAH is 9.1 per 100,000 person-years (95% confidence interval, CI: 8.8-
9.5), according to a meta-analysis of 51 studies from 21 countries.5 The incidence increase 
with age, leveling off at the sixth decade. The incidence of aSAH is 50-70% higher in women 
than men,6, 7 with the female preponderance occurring after 50 years of age.5 
 Regional variations exist, with the highest incidence in Finland (19.7 per 100,000 
person-years, 95% CI: 18.1-21.3) and Japan (22.7 per 100,000 person-years, 95% CI: 21.9-
23.5), whereas the lowest incidence is observed in South and Central America (4.2 per 
100,000 person-years, 95% CI: 3.1-5.7).5 These differences are explained by regional 
differences in demography, genetic factors, case finding, and prevalence of risk factors for 
aSAH at the population level.5 Only one study has investigated within-country differences in 
the incidence of aSAH. This study from Sweden found that the incidence rates increased from 
south to north, with a mean incidence of 11.3 per 100,000 person-years.8 Previous regional 
studies of aSAH in Norway have found varying incidence, from 9.9 to 25.6 per 100,000 
person-years.9-12 This indicates that regional differences also exist in Norway. 
 Temporal trends in the incidence of aSAH are uncertain, as a result of small number of 
patients with aSAH in incidence studies, and increased diagnosis of aSAH in the 1990s due to 
increased availability of computed tomography.13 In the aforementioned meta-analysis, a 
0.6% annual decrease in the incidence of aSAH was observed between 1955 and 2003.5 This 
is moderate compared to the decline of other types of stroke in industrialized countries.14-16 It 
is therefore uncertain whether implementation of stroke preventive treatments and reductions 
in cardiovascular risk factors, at the population level, have translated into a reduction of 
aSAH episodes. 
 
3.3  Risk factors for aSA H 
In a meta-analysis of 14 prospective cohort studies on risk factors for aSAH, the statistically 
significant risk factors for aSAH were current smoking (relative risk, RR: 2.2, 95% CI: 1.3-
3.6), hypertension (RR: 2.5, 95% CI: 2.0-3.1), and excessive alcohol consumption (>150 g 
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per week, RR: 2.1, 95% CI: 1.5-2.8).17 Ethnicity, use of oral contraceptives or hormone 
replacement therapy, were not statistically significant risk factors.  
The association between body mass index, serum lipids, and the risk for aSAH is 
unclear. Some studies have reported a risk reduction with increasing body mass index or 
serum lipids,12, 18-23 whereas other studies have found no such association.10, 24, 25 
In a meta-analysis of prospective studies18, 25-34, the risk for ever-smoking women (RR 
2.7, 95% CI: 1.8-4.1) were 1.9 times higher than ever-smoking men (1.4, 95% CI: 0.9-2.1), 
compared to non-smokers. No sex differences in current smoking were observed (for women: 
RR 2.2, 95% CI: 1.7-2.8; for men: RR 2.2, 95% CI: 1.7-3.0). Hypertension was more 
hazardous in women (RR 3.3, 95% CI: 2.1-5.3) than men (RR 2.3, 95% CI: 1.8-3.0). No sex 
differences were observed with respect to excessive alcohol consumption, defined as >150 g 
per week. (RR 4.0, 95% CI: 0.8-19.1 in women. RR 2.2, 95% CI: 1.5-3.2 in men).17 
Retrospective case-control studies have reported conflicting results. One study found 
statistically significant increased risk of aSAH in male compared to female smokers,35 another 
study found statistically significant higher risk of aSAH in female compared to male 
smokers,36 whereas other studies found no statistically significant sex differences.18, 37-40 
 
3.4  The gender gap in aSA H 
The female preponderance in incidence of aSAH is caused by a corresponding female 
preponderance in the prevalence of intracranial aneurysms.41 In other parts of the arterial 
vasculature, the prevalence of aneurysms is higher in men than women (abdominal aortic 
aneurysms are found four times more often in men than in women).42 The gender gap in 
aSAH has been sparsely investigated, and the suggested explanations are systemic factors 
such as hormonal influences and intrinsic weakness of the female arterial wall.19, 43 
Epidemiological studies have found that premenopausal females are at reduced risk for SAH 
compared with age-matched postmenopausal females.5, 44 The increased risk after age 50 has 
been attributed to the influence of hormonal factors, however studies on the use of oral 
contraceptives and hormone replacement therapy on the risk for SAH have yielded conflicting 
results.19, 45-47 The second theory for the gender gap, intrinsic weakness of the female arterial 
wall, remains to be proven.43  
The sex difference in the prevalence of intracranial aneurysms is not constant, but 
varies with the different intracranial arteries: women have more aneurysms in the internal 
carotid, middle cerebral, and basilar artery, whereas anterior cerebral artery aneurysms are 
equally encountered in men and women.43, 48-50 This uneven distribution proposes a 
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physiological factor: local sex differences in the different intracranial arteries. Sex differences 
in local hemodynamic stress of the intracranial arteries have not been subject to scientific 
studies. However, such sex differences are plausible as aneurysms arise where arteries are 
exposed to the maximum hemodynamic forces. And the hemodynamic forces vary with the 
different intracranial arteries due to geometrical differences.51, 52 
 
3.5 Computational fluid dynamics simulation 
The hemodynamic forces acting upon the arterial wall are not possible to measure directly in 
patients, but can be estimated with computational fluid dynamics simulation. Computational 
fluid dynamics simulation is a technique traditionally used in engineering to simulate the 
forces acting upon for instance turbines and oil pipes. Biomechanical application allows 
simulation of blood flow throughout arteries and calculation of the resulting hemodynamic 
forces acting upon the arterial wall. The simulations involve discretizing the vessel into small 
cells to form a volume mesh, and then applying algorithms to solve the equations of motion. 
The motion of viscous fluids is described by the Navier-Stokes equation, which is solved for 
each cell. In the present thesis, computational fluid dynamics simulations are used to calculate 
a hemodynamic force named wall shear stress. When blood (a Newtonian fluid, i.e. a fluid 
that has a constant	  viscosity	  at	  a	  given	  temperature) flows along the vessel wall, a stress 
will be applied parallel to the vessel wall; this is called wall shear stress. Shear stress at a 
point is given by: 
 
 × ( / y) 
 
 is the dynamic viscosity of blood,  is the dynamic velocity of the blood along the vessel 
wall, and y is the diameter of the vessel. Abnormal shear stress has been suggested as a 
causative factor in the formation and rupture of intracranial aneurysms.53-55 
	   10	  
4 A I MS O F T H E T H ESIS 
 
I To study the incidence of aSAH in Norway, with a focus on time trends and regional 
variations 
 
II To study serum lipids and body mass index as risk factors for aSAH 
 
III To study sex differences in the established risk factors for aSAH (smoking, 
hypertension, and alcohol consumption) 
 
IV To explore a new hypothesis for the female preponderance of intracranial aneurysms 
and aSAH: that sex differences in vessel size and blood flow velocity result in higher 
hemodynamic forces acting upon the female arterial wall. 
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5 M A T E RI A L A ND M E T H O DS 
 
5.1 Pap  
 
5.1.1 Data source 
Data were collected retrospectively from the Norwegian Patient Register, the national hospital 
discharge registry. For each hospital discharge, date of admission and discharge, discharge 
destination (home, another hospital, death), procedure codes, hospital identification code, 
gender, age and county of residence were recorded. One main diagnosis and a set of 
secondary diagnoses indicating co-morbidities were recorded. During the study period, the 
data from the Norwegian Patient Register contained no patient identifiers that would allow 
tracking of repeat hospitalizations. 
 
5.1.2 Inclusion and exclusion criteria 
We identified all cases with a diagnosis of non-traumatic SAH admitted to Norwegian 
hospitals from January 1st, 1999 to December 31st, 2007, using the codes I60.0 I60.9 from 
the International Classification of Diseases, version 10. January 1, 1999 was chosen as the 
starting point for this study as this represents the date when version 10 of the International 
Classification of Diseases was implemented in Norwegian hospitals. As one could not assume 
that each hospitalization represents an individual patient and that all SAHs were aneurysmal, 
the following strategies were used: (i) We excluded cases that were not admitted as an 
emergency. (ii) We excluded admissions to non-neurosurgical hospitals if the patient survived 
>2 days. This was done to eliminate non-aSAHs and repeated hospitalizations as a result of 
transfer between hospitals. (iii) We excluded hospitalizations in neurosurgical centers if 
length-of-stay was <3 days and if discharge destination was home. This was done to eliminate 
re-admissions, as the lack of unique patient identifiers precluded the tracking of patients who 
were transferred between hospitals. (iv) We excluded cases with secondary diagnoses of 
arteriovenous malformation (Q28.2) or traumatic SAH (S06). 
The Norwegian Data Inspectorate, the Norwegian Board of Health, and the Regional 
Committee for Medical Research Ethics approved this study. 
 
5.1.3 Sample 
Using the appropriate ICD-10 codes for SAH, we identified 11,618 hospital admissions in 
Norway between January 1, 1999 and December 31, 2007. Of these, 7475 were excluded 
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according to the pre-established exclusion criteria, leaving a total of 4,143 patients available 












F igure 5.1 Flowchart of patient inclusion, Paper I 
 
5.1.4 Statistical analyses 
The source population consisted of all Norwegian citizens with 41.3 million person-years at 
risk, compiled from annual census data between 1999 and 2007, by gender, age and region. 
The annual incidence rates were calculated by dividing the number of all events by person-
years, after direct standardization to the entire study period (1999  2007). To analyze regional 
differences in incidence rates, the 19 Norwegian counties were allocated into five areas based 
on the Norwegian Regional Health Authorities; southern (Telemark, Buskerud, Vestfold, 
Vest-Agder and Aust-Agder), western (Rogaland, Hordaland and Sogn og Fjordane), eastern 
(Akershus, Østfold, Oslo, Hedmark and Oppland), central (Sør Trøndelag, Nord Trøndelag 
and Møre og Romsdal) and northern (Nordland, Troms and Finnmark). The number of cases 
never reaching hospital alive was calculated by subtracting the number of hospitalized 
patients with fatal outcome from the total number of deaths caused by SAH from the 
Norwegian Causes of Death Registry. Analysis of overall P for trend over time was 
performed using annual incidence and mortality rates of SAH. The overall national mortality 
rates were established from statistics published by the Norwegian Causes of Death Registry, 
were available from 1999 through 2006. Data from 
2007 were not available at the time of analysis. 
 
Patients with hospital discharge diagnosis of aSAH: 11,618  
Excluded due to: 
i)   Non-emergency admission:      3,112 
ii)  Admission to a non-neurosurgical hospital and survival >2 days:  4,061 
iii) Hospital length-of-stay <3 days and discharge to home:      118 
iv) Diagnosis of arteriovenous malformation or traumatic SAH:     184 
Patients included in the analysis: 4,143 




5.2.1 Study population 
The Tromsø study and Nord-Trøndelag Health Study (HUNT) are two prospective, 
population-based cohort studies. The Tromsø study is conducted in the municipality of 
Tromsø, Troms county, Norway, and the HUNT study is conducted in the county of Nord-
Trøndelag, Norway. The design of both studies includes repeated population health surveys to 
which total birth cohorts are invited. 
The fourth survey of the Tromsø study (Tromsø 4) was conducted between 1995 and 
1997. All residents aged 25 and older were invited to participate. Of the eligible population, 
27,158 participated (77%).56 Two-hundred-and-seventy-six participants were excluded 
because of not consenting to medical research (n=201), not officially registered as inhabitants 
of the municipality at the date of attendance (n=44), or previous SAH (n=31), leaving a total 
of 26,882 subjects to be followed up in the present analyses. 
The second survey of the HUNT study (HUNT 2) was conducted between 1995 and 
1997, and all residents aged 20 years and older were invited to participate. Of the eligible 
population, 65,628 participated (71.2%).57 In Paper III, 48 persons were excluded because of 
death (n=3), not officially registered as inhabitants of the county at the date of attendance 
(n=2), or previous SAH (n=43) before entering the study, leaving a total of 65,580 
participants to be followed up in the present analyses. The combined cohort of Paper III 
consisted of 92,462 persons, with 1,002,148 person-years of observation. 
After Paper III had been published, we became aware of a data file error concerning 
the HUNT cohort. A total of 55 participants (not 2) were not registered as inhabitants of the 
municipality at the date of attendance. One participant with previous SAH had erroneously 
not been classified as such. Furthermore, 12,711 persons that moved from Nord-Trøndelag 
county during the follow-up period had erroneously been assigned follow-up time to the end 
of follow-up and not to the date of emigration. This was corrected in Paper II, in which 102 
participants were excluded because of death (n=3), not officially registered as inhabitants of 
the county at the date of attendance (n=55), or previous SAH (n=44) before entering the 
study, leaving a total of 65,526 participants to be followed up in the present analysis. The 
combined cohort of Paper II consisted of 92,408 persons. After correcting the follow-up time 
of the 12,711 persons that emigrated from the HUNT study area, the total follow-up time was 
reduced from 1,002,148 to 977,895 person-years. This has been corrected in Paper II. 
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The Norwegian Data Inspectorate, the Norwegian Board of Health, and the Regional 
Committee for Ethics in Medical Research approved this study. All participants gave their 
informed, written consent to participate. 
 
 
5.2.2 Data source 
In the Tromsø 4 and HUNT 2 surveys, information on cardiovascular risk factors, 
menstruation status, and use of antihypertensive treatment, and hormone replacement therapy 
at baseline was obtained by self-reported questionnaires and physical examinations.56,57  
Based on the self-
classified as never (reference category), former, or current smoking. Alcohol consumption 
was classified as abstinent, drinking <1 time per month (reference category), 1-4 times per 
month, and >4 times per month. Height and weight were measured with the participants 
wearing light clothes without shoes; height was measured to the nearest cm and weight to the 
nearest half kg. Body mass index was calculated as weight (kg) divided by the squared value 
of height (m). In the analysis, body mass index was treated both as a continuous variable and 
according to weight groups defined by the World Health Organization: <18.5 as underweight, 
18.5-24.9 as normal weight, 25- 2 as obese. In the 
categorical analyses, we used the normal weight group as the reference. 
Blood pressure was measured in a seating position by trained nurses using an 
automatic device (Dinamap, Critikon, Tampa, FL, USA). Cuff size was adjusted after 
measuring the arm circumference. After 2 min of seated resting, three recordings were made 
at 1-min intervals. The mean value of the second and third measurement was used in the 
analysis. Hypertension was defined as systolic blood pressure >140 mmHg or current use of 
antihypertensive drugs. Women who did not use hormone replacement therapy were classified 
as premenopausal if they were still menstruating. Women who were not pregnant or no longer 
menstruating, women who were hormone replacement therapy-
years were classified as postmenopausal. 
A non-fasting blood sample was drawn from all participants. Serum samples were 
analyzed for total cholesterol, high-density lipoprotein-cholesterol (HDL cholesterol), and 
triglycerides on a Hitachi 911 Autoanalyzer, by enzymatic colorimetric methods with 
commercial kits (CHOD-PAP, Boehringer-Mannheim) at the Central Laboratory at Levanger 
Hospital (HUNT 2) and at the Department of Laboratory Medicine, University Hospital of 
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North Norway (Tromsø 4). Serum HDL cholesterol was measured after the precipitation of 
lower-density lipoprotein with heparin and manganese chloride.  
 
5.2.3 Inclusion and exclusion criteria 
Patients were included as aSAH cases if the diagnosis had been verified by cerebral 
angiography or autopsy, or if the medical history was highly suggestive for fatal aSAH, but 
the patient had died before undergoing cerebral angiography and was not autopsied. A 
medical history highly suggestive of fatal aSAH was defined as (i) sudden headache and/or 
unconsciousness, (ii) death < 4 weeks, and (iii) findings on non-contrast enhanced computed 
tomography scans were typical for aSAH (massive basal SAH). All criteria had to be fulfilled. 
In HUNT, all cases were reviewed and consented by two neurosurgeons. In the Tromsø 
Study, an independent endpoint committee of one neurologist and two experienced physicians 
validated the aSAH cases. A neurologist and a neuroradiologist validated cases suggestive for 
fatal aSAH. 
 
5.2.4 Case identification 
The national 11-digit identification number allowed linkage of the baseline data to national 
and regional registers, and ensured a complete follow-up status for all-cause mortality. For the 
HUNT population, information about SAH was obtained by linkage to the diagnosis register 
at St Olavs University Hospital, the only hospital with a neurosurgical department serving the 
HUNT population. All patients who survive the acute phase of the SAH are treated at the 
department, and people who live in the region but experience a nonfatal SAH outside the area, 
are usually transferred to the department after acute treatment elsewhere. An identical 
procedure was followed in the Tromsø Study, using information from the University Hospital 
of North Norway, the only hospital in the area that serves the study participants. Further, 
information from both studies was linked to the National Causes of Death Register at 
Statistics Norway, using codes for aSAH according to the International Classification of 
Diseases, version 9 (code 430) and 10 (code I60). Individuals who had died or emigrated from 
Nord-Trøndelag or Tromsø were identified through the Population Register of Norway. Data 
on emigration from the study areas were available from the Population Register of Norway. 
Follow-up time was assigned from the date of examination in each study (from 1994 
to 1997) until the first aSAH occurred, until death from other causes, emigration, or to the end 
of follow-up, December 31, 2007, whichever occurred first. Hospitals charts for the identified 
patients were reviewed. Case fatality was defined as death 30 days after aSAH. 
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5.2.5 Sample 
We identified 120 incident cases of aSAH (102 verified by angiography or at autopsy and 18 
with a medical history highly suggestive of fatal aSAH). Of these patients, 69 were from the 
Nord-Trøndelag and 51 from the Tromsø cohort. After Paper III had been published, the 
search for aSAH cases was extended, and two additional incident aSAH cases were found. 
This was corrected in Paper II, leaving a total of 122 incident cases of aSAH (103 verified by 
angiography or at autopsy and 19 with a medical history highly suggestive of fatal aSAH). Of 
these patients, 71 were from the Nord-Trøndelag and 51 from the Tromsø cohort. 




F igure 5.2 Flowchart of patient inclusion (Paper II) 
 
5.2.6 Statistical analyses 
Cox proportional hazards model was used to estimate hazard ratios (HRs) of aSAH with 95% 
CI. The analyses were stratified by sex. The analyses were performed with and without the 18 
aSAH-patients that were not verified by angiography or at autopsy. Departure from the 
proportional hazards assumption was evaluated by Schönfel
Participants - Tromsø 4: 27,158 
Excluded due to: 
- No consent: 201 
- Not inhabitant in Tromsø:   44 
- Previous aSAH:      31 
Combined cohort Tromsø 4 and Hunt 2: 92,408 
Participants  HUNT 2: 65,628 
Excluded due to: 
- Death before entering study:    3 
- Not inhabitant in:     55 
 Nord-Trøndelag:      
- Previous aSAH:    44 
Participants without aSAH: 92,286 
Cases with aSAH verified by 
angiography or autopsy: 103 
Cases with medical history 
of fatal aSAH: 19 
Participants with aSAH: 122 
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the log-log plots. Possible statistical interaction between sex and the risk factors for aSAH 
(hypertension, smoking and alcohol consumption) was assessed using the log likelihood ratio 
test. Possible biological (i.e. additive) interaction between sex and the risk factors for aSAH 
was assessed by calculating the relative excess risk due to interaction (RERI) with 95 % 
CIs.58-60 RERI values >0 indicate increased risk of aSAH associated with the risk factor in 
question among women as compared to men, and RERI values <0 indicate decreased risk of 
aSAH associated with the risk factor among women as compared to men. All analyses were 




5.3.1 Study population 
Data from a previously published study of 55 patients undergoing diagnostic cerebral digital 
subtraction angiography were available for analysis.61 The indications for cerebral 
angiography were acute or previous SAH, ischemic cerebrovascular events, symptoms 
suspicious of other cerebrovascular disease, or family history of intracranial aneurysms. 
 
5.3.2 Data source 
We evaluated bifurcation geometry by analyzing measurements of vessel radii and bifurcation 
angles on three-dimensional reconstructions of the digital subtraction angiograms. The 
terminal bifurcation of the internal carotid artery and the division of the M1 segment of the 
middle cerebral artery into two main branches were studied. Five measurements were 
performed: diameter of the parent vessel, largest branch, and the smallest branch; and the 
angle formed between the parent vessel and the largest branch and the smallest branch, 
respectively. The diameter of the parent vessel was measured midway between the last branch 
point and the bifurcation of interest. In the branches, the diameters were measured 5 mm 
beyond the apex of the bifurcation, or if a new branch arose before this, at the most distal 
location before the next bifurcation. These points were identified on oblique images oriented 
along the flow axis of the vessel. The diameters were measured at eight different centripetal in 
a plane oriented 90 degrees on the flow axis. In order to measure the bifurcation angles, three 
points were defined in the three-dimensional volume to measure an angle: the center of the 
parent vessel at the point where the diameter was measured, the center of the bifurcation, and 
the center of the branch at the point where the diameter was measured.61 
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 The average radii and angles were calculated and idealized male and female models of 
the middle and internal cerebral artery bifurcations were developed using Star-CD (pro-STAR 
Version 3.26.003, CD-Adapco, New York, USA). The models were smoothed in the 
intersections to give physiological correct appearance. The vessel length was set at 20 mm for 
the parent vessel and 15 mm for the branches, enabling fully developed flow at the outlets.  
 
5.3.4 Sample 
Of the 55 available patients, six patients with only imaging of the basilar artery were 
excluded, leaving data from 49 patients (32 females and 17 males) with available angiograms 
of the middle cerebral (n=52) or internal carotid artery (n=47) available for analysis.  
 
5.3.5 Computational fluid dynamics simulations 
Computational fluid dynamics simulations were used to calculate hemodynamic forces in the 
models. Earlier published data on average sex specific blood flow velocities (mean flow 
velocity: 75 cm/s for the female middle cerebral artery, 64 cm/s for male middle cerebral 
artery; 42 cm/s for the female internal carotid artery, and 34 cm/s for the male internal carotid 
artery) were used as stationary inflow boundary condition to the numerical simulations.62 We 
modeled blood as a Newtonian incompressible fluid with density of 1025 kg/m3 and viscosity 
of 0.0035 kg/m×s. The vessel walls were assumed rigid. To represent the downstream 
geometry, the outlets were assigned a resistance boundary condition of the form R=p0+C×Q, 
where p0 is the pressure (85 mmHg), Q is the flow rate, and C is the resistance coefficient 
(5.97 Pascal×seconds×meters-3).63 The Navier-Stokes equations, describing the flow, were 
solved using the finite element method, with a Chorin/Temam splitting scheme using second 
order elements in space.64, 65 Tests showed that approximately 2×105 cells were sufficient to 
achieve numerical convergence. The code was implemented in FEniCS (www.fenics.org). 
 
5.3.6 Statistical analyses 
Preliminary assumption testing was conducted to check for normality, linearity, and 
univariate outliers. No notable violations were found, permitting the calculation of means, 
standard deviations and use of independent samples t-test when comparing between groups. 
Probability values are two-tailed. SPSS release 15.0 (SPSS, Inc., Chicago, IL) was used for 
calculations. The computational simulations could not be subjected to statistical tests.
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6 SU M M A R Y O F R ESU L TS 
 
6.1  
The crude incidence rate of aSAH in Norway between 1999 and 2007 was 10.0 per 100,000 
person-years (95% CI: 9.7  10.3). The incidence was higher in women (12.0 per 100,000 
person-years; 95% CI: 11.5 12.5) than men (8.1 per 100,000 person-years; 95% CI: 7.7 8.4). 
The crude overall mortality rate was 3.2 per 100,000 person-years (95% CI: 3.0 3.4).  
A significant decrease in annual incidence was observed in the period, from 11.1 per 
100,000 person-years (95% CI: 10.5 11.6) in the period 1999 2001 to 8.9 per 100,000 
person-years (95% CI: 8.4 9.4) in the period 2005 2007 (P for trend <0.001), with a 
concurrent decrease in the annual mortality rate of SAH, from 3.5 per 100,000 person-years in 
1999 2000 (313 cases), to 2.9 per 100,000 person-years in 2005 2006 (266 cases; P for trend 
0.02).  
Regional variations were observed in incidence rates, from 8.4 per 100,000 person-
years (95% CI: 7.7 9.0) in the southern region, 10.4 per 100,000 person-years (95% CI: 9.5
11.2) in the central region, to 11.9 per 100,000 person-years (95% CI: 10.8 12.9) in the 
northern region, adjusted for gender and age. The highest incidence of aSAH was found in the 
northernmost county Finnmark with 17.4 per 100,000 person-years (95% CI: 14.2 20.5).  
 
6.2 - body mass index and se  
A total of 122 aSAH cases were identified over 977,895 person-years of observation.  
There was a positive association between female sex (HR 1.9, 95% CI: 1.3-2.7), 
systolic hypertension (HR 2.6, 95% CI: 1.6-3.7), current smoking (HR 5.7, 95% CI: 3.4-9.4), 
and the risk of aSAH. Overweight (body mass index 25.0-29.9) participants were at lower risk 
of aSAH, compared to normal weight (body mass index 18.5-24.9) participants (HR 0.7, 95% 
CI: 0.4-1.0, adjusted for age, sex, smoking and alcohol consumption. 
Among participants <50 years of age, a statistically significant, inverse relationship 
between HDL cholesterol and the risk of aSAH was observed (HR 0.6, 95% CI: 0.4-0.9, 
adjusted for sex, age, smoking, and alcohol consumption). No further association between 
total serum cholesterol, HDL cholesterol, triglycerides or alcohol consumption, and the risk of 
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6.3  
A total of 120 aSAH cases were identified over 1,002,148 person-years of observation. Mean 
age at diagnosis was 58.6 years for women (standard deviation, SD 1.6, range 35-90) and 58.9 
years for men (SD 2.1, range 30-87). On average, aSAH was diagnosed 72 months after 
baseline measurements (SD 43, range 0-147 months). The 30-day case fatality for aSAH was 
38% (n=30) for women and 39% (n=16) for men. 
In these sex-specific analyses, increased risk of aSAH was observed in female 
compared to male current smokers. The sex difference in current cigarette smoking increased 
after adjusting for age and alcohol consumption (HR 8.9 for women, 95% CI: 4.7-17.0, vs HR 
2.8 for men, 95% CI: 1.3-6.1) The RERI for sex and current cigarette smoking was 3.1 (95% 
CI 0.5-5.8), indicating significant higher risk of aSAH associated with current cigarette 
smoking in women than in men (additive or biological interaction). 




The diameters of the male vessels were significantly larger than the female vessels (p<0.05), 
with the exception of the largest branch of the internal carotid artery. No significant sex 
differences in the bifurcation angles were observed. 
Computational fluid dynamics simulations based on averaged models showed both 
increased wall shear stress and a larger affected area in the female middle cerebral artery and 
internal carotid artery bifurcations. The maximum wall shear stress in the middle cerebral 
artery was 19 % higher in the female bifurcation (33.2 Pascal, Pa) than the male (27.8 Pa). 
The maximum wall shear stress in the internal carotid artery was 50 % higher in the female 
bifurcation (15.2 Pa) than in the male (10.1 Pa). These values were reflected through a higher 
pressure drop in the female than the male bifurcations (664 versus 502 Pa for the middle 
cerebral artery and 344 versus 202 Pa for the internal carotid artery).  
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7 DISC USSI O N 
 
The main findings of this thesis are: (i) that the incidence of aSAH in Norway decreased from 
1999 to 2007, with significant regional variations indicating an increasing gradient from south 
to north; (ii) overweight is inversely associated with the risk of aSAH, compared to normal 
weight, but no overall association between HDL, LDL, total serum cholesterol, triglycerides, 
and the risk for aSAH is observed; (iii) current cigarette smoking is a stronger risk factor for 
aSAH in women than in men; and (iv) sex differences in arterial size and blood flow velocity 
result in higher hemodynamic forces acting upon the female arterial wall. 
 
7.1 Internal and external validity of the studies 
Internal validity is defined as validity of inference for the source population of study subjects. 
Three types of errors may threaten the internal validity: (i) selection bias: distortions that 
result from procedures used to select subjects and from factors that influence study 
participation; (ii) information bias: different consequence of errors in the measurement of 
exposure and/or disease in subjects; and (iii) confounding factors: the extraneous factors 
responsible for difference in disease frequency between the exposed and unexposed. 
External validity pertains to the ability to generalize the findings to the general 
population.66 
  
7.1.1 Paper I 
Paper I describes a sample selected from a non-validated, national hospital discharge registry 
without person identifiers. Possible selection bias includes regional and temporal differences 
in the hospitalization of patients with suspected aSAH. This may explain the somewhat higher 
observed age- and sex-adjusted incidence rates in counties where the five hospitals with 
neurosurgical wards are located than in the surrounding counties. However, patients with 
aSAH have serious symptoms (such as severe headache with rapid onset and/or loss of 
consciousness), and usually reach medical attention rapidly. Thus, the number of patients 
hospitalized for aSAH probably closely represents the true number of aSAH cases. As the 
Norwegian Patient Register did not contain patient identifiers, a validation study was not 
possible. However, a Swedish study comparing the 
 
(MONICA) stroke registry with hospital discharge registries, found that 94% of incident 
stroke cases was registered in the Swedish national hospital discharge registry.67 
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Information bias may exist due to measurement errors (erroneous inclusion of non-
aSAH cases or classification of aSAH cases as healthy, and counting aSAH cases more than 
once), as hospital discharge registries are prone to errors in coding. In order to prevent this, a 
number of precautions were taken to eliminate non-aSAHs, readmissions and repeated 
hospitalizations as a result of transfer between hospitals, as described in the Methods section. 
Further, erroneous classification of rebleedings as incident cases may have artificially 
increased the estimated incidence rates. As the risk of rebleeding is low after surgical or 
endovascular treatment (1.3% during the first 8 years following the first episode),68 the effect 
would be small. However, as long as these measurement errors affected the comparison 
groups (time periods and regions) equally, the resulting information bias would be non-
differential. 
Confounding factors, such as distance to a neurosurgical ward and availability of 
radiological imaging may exist. However the serious symptoms of aSAH, the widespread 
availability of computed tomography in Norway since mid-1990s, and the extensive air 
ambulance service in remote parts of Norway, make it less likely that his has affected the 
observed incidence rates. 
As the study population was drawn from the entire Norwegian population, the findings 
may be generalized to the general population on the condition that the study is internally 
valid. In conclusion, the internal validity of Paper I is limited by the identification of cases 
from a national hospital discharge registry that did not include patient identifiers, and this 
precluded a validation study. Nevertheless, the observed incidence rates are in accordance 
with incidence rates observed from other Western European countries,5 implying that the 
findings of Paper I are valid. 
 
7.1.2 Paper II and III  
Paper II and III describe a prospective cohort. In prospective cohort studies, selection bias is 
negligible with respect to the association between risk factors and disease, as information on 
exposure is ascertained before the development of disease. 
The possibility of information bias in outcome is limited, but may be caused by either 
erroneous classification of healthy as SAH cases or SAH cases as healthy. The former is 
unlikely due to the rigorous case validation, whereas the latter is possible due to deaths 
outside hospital that were not autopsied.  
After Paper III was published, the identification of aSAH cases was extended and two 
additional incident aSAH cases identified, as well as one participant with previous SAH. In 
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Paper III, data on participants that emigrated from the HUNT study area during follow-up 
were not available. Censoring these patients reduced the total follow-up time with 1,002,148 
 977,895 = 24,253 person-years. The error introduced by this is limited due to the large 
number of participants and aSAH cases, and is therefore unlikely to change the effect 
estimates of Paper III. 
The number of out-of-hospital deaths caused by aSAH is difficult to measure. A meta-
analysis of 18 population-based studies found that 12.4% of aSAH patients died before 
receiving medical attention.69 Another study of 142 survivors after out-of-hospital cardiac 
arrest found aSAH in 16.2% of the patients.70 This implies that out-of-hospital deaths 
occasionally are caused by aSAH. As only a minority of out-of-hospital deaths is autopsied, it 
is likely that some cases of sudden aSAH deaths in the present study have erroneously been 
classified as healthy. Biased estimates of the association between exposure and disease may 
also be caused by errors in exposure measurements. The present study examined exposure 
data from self-reported questionnaires (smoking status, alcohol consumption, use of hormone 
replacement therapy, and menstruation/menopause status) and laboratory measurements 
(blood pressure, non-fasting serum lipids (triglycerides, HDL-, LDL, and total-cholesterol). 
With respect to the self-reported questionnaires, possible bias includes recall bias. With 
respect to the laboratory data, there may be errors in measurement due to variations in the 
measured variables. There is a circadian variation in blood pressure,71 and blood pressure 
increases in a clinical setting (the white coat effect).72 To minimize this potential error, blood 
pressure was measured three times by trained nurses using an automatic device and the mean 
value of the second and third measurement was used in the analysis. Non-fasting serum lipids 
were used in the Tromsø study. Whereas there is considerable variation in triglyceride levels 
throughout the day (>20%), the circadian variation in HDL-, LDL-, and total-cholesterol is 
negligible (<10%).73 However, as exposure data in cohort studies are measured before disease 
occurrence, the potential measurement errors can be assumed to be non-differential with 
respect to disease.  
The observed sex differences may have been caused by unknown confounding factors 
we were unable to adjust for. One might speculate whether the observed sex differences are 
caused by changes in risk factors levels that occurred during follow up. Unpublished data 
from the Tromsø study show that this is less likely (Table 7.1). Further, information on family 
history of stroke (hemorrhagic and ischemic) and not subtypes of stroke (aSAH) was 
available. 
	   24	  
In the present study, the analysis of hereditary factors as a risk factor for aSAH and 
possible interaction between smoking and hereditary factors are not specific for aSAH, but 
include hereditary factors for stroke in general. 
Due to the high response rate and the prospective, population-based, cohort design to 
which total birth cohorts were invited, there are probably no major threats to the external 




 Percentage of current smokers  






Men    
  30-39 years 39.0 29.6 21.1 
  40-49 years 40.4 33.6 21.2 
  50-59 years 37.6 36.9 20.2 
  60-69 years 34.9 27.1 16.9 
  70-79 years 26.8 21.7 16.5 
  80-84 years 20.9 18.2 10.5 
Women    
  30-39 years 40.9 43.8 25.0 
  40-49 years 42.8 35.9 25.9 
  50-59 years 36.7 31.4 25.0 
  60-69 years 30.8 28.1 19.8 
  70-79 years 17.8 18.4 14.5 
  80-84 years 8.7 12.2 6.8 
 
Table 7.1 Percentage of current smokers among men and women who attended the fourth 
survey of the Tromsø study, by age and survey 
 
 
7.1.3 Paper IV 
Paper IV describes computational fluid dynamics simulations based on radiological 
measurements of the middle cerebral and internal carotid artery in consecutive patients 
undergoing diagnostic cerebral angiography. Selection bias is possible, as the study 
population was small and the sample size skewed, with a female-to-male ratio of almost 2:1. 
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Further, the study population consisted of patients undergoing diagnostic angiography, and 
not healthy volunteers, only the middle cerebral and internal carotid artery were examined, 
and the computational fluid dynamics simulations were based on idealized male and female 
models, developed from the geometric measurements, and not patient specific models. 
Information bias is possible in either the measurements of the vessels or in the 
computational fluid dynamics simulations. The former is unlikely due to high inter- and 
intraobserver agreement, whereas the latter is possible as computational fluid dynamics is an 
evolving method. Further, the analysis did not include sex differences in dynamic blood 
viscosity  one of the parameters that determine shear forces. Several factors contribute to the 
viscosity of blood: the number of red blood cells (higher in men), the number of plasma 
proteins (such as fibrinogen, higher in women), and body temperature. Blood viscosity in 
women varies with the menstrual cycle and menopause status.74 Although blood viscosity is 
somewhat higher in men than women,75 it was difficult to determine the precise values for 
blood viscosity in the intracranial arteries, and the same value was used for both genders in 
the simulations. It is not unlikely that adjusting for sex differences in blood viscosity would 
somewhat attenuate the observed sex differences in shear forces. There may also be other 
confounding factors that, if different between females and males, produce different 
mechanical loads on the arterial walls in men and women. 
In conclusion, the results of Paper IV must be interpreted with caution. The hypothesis 
presented, that sex differences in anatomy and blood flow velocity cause the gender gap in 
aSAH, deserves prospective investigation in future studies. 
 
7.2 The incidence of aSA H 
Paper I found that the crude incidence of aSAH in Norway decreased from 11.1 per 100,000 
person-years (95% CI: 10.5 11.6) in the period 1999 2001 to 8.9 per 100,000 person-years 
(95% CI: 8.4 9.4) in the period 2005 2007. Significant regional variations were observed, 
indicating an increasing gradient from south to north. 
The decline in the incidence of aSAH is congruent with results from a meta-analysis 
covering populations in 21 countries.5 Possible explanations include a coincidental decline in 
the prevalence of unfavorable risk factors. The number of daily smokers in Norway aged 16
74 years declined from 34% in 1996 to 24% in 2006.76 Among 40 42-year-old men, the 
1999. The corresponding decline in women was from 2.1% to 1.3%.77 The larger decline of 
incidence rates in men than in women may partially be explained by the fact that the 
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percentage of female smokers remained unchanged for about 30 years until 2003, whereas the 
percentage of male smokers dropped significantly during the same period.76 The role of 
cardiovascular risk factors is further supported by the high incidence rate in Finnmark, a 
county that for several decades has had a higher mortality of ischemic heart disease and stroke 
than the other counties in Norway.78 It is unlikely that increased treatment of unruptured 
aneurysms has significantly influenced the decline in incidence rates, as the annual rupture 
rate for incidentally discovered aneurysms is low.68 
The observed regional variations in the incidence rates of aSAH were as reported for 
Sweden, with a higher incidence rate in the northern region compared with the southern 
region.8 A possible explanation for the regional variations in incidence rates is regional 
variations in the risk factors of aSAH (such as smoking and blood pressure).  As mentioned 
before, the northernmost county in Norway, Finnmark, has for several decades had a higher 
mortality of cardiovascular diseases than the other Norwegian counties.78 Smoking is more 
frequent in the eastern and northern parts of Norway compared with the southern and western, 
with the highest prevalence in the northernmost county Finnmark.76 There are, however, no 
corresponding geographical differences in blood pressure distribution in the general 
population.79 The Finnmark population is a mixture of Sami, Norse and Finnish descendents. 
Possibly, a larger proportion of the population of Finnish heritage in Finnmark may contribute 
to the higher incidence rates of aSAH, as the population of Finnish heritage in Finnmark has a 
higher incidence of unfavorable risk factors and ischemic disease than the general 
population,78 and the incidence of aSAH is higher in Finland than in other parts of the 
world.13 
The age- and sex-adjusted incidence rates are higher in counties with neurosurgical 
wards than in the surrounding counties. This might be due to easier access to high-specialized 
hospital services, resulting in better diagnostic precision and higher hospitalization rate for 
people living in these areas. One might also speculate whether the higher incidence rate 
observed in the capital county Oslo could be partly attributed to a relatively high proportion 
of immigrants from low-income countries. The proportion of people with ancestry from Asia, 
Africa, Latin America, European countries outside the European Union and Oceania, except 
Australia and New Zealand, is 19.5% in Oslo, whereas the average for Norway is 6.7%. 
Increased incidence of cardiovascular disease in persons migrating from poorer countries to 
high-income industrialized countries is thought to be a result of unfavorable changes in 
dietary and other life-style habits with increased exposure to cardiovascular risk factors. 
Similar changes are seen in developing countries. Feigin et al. found that incidence rates for 
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SAH in the period 2000 2008 were almost twice as high in low- to middle-income countries 
compared with high-income countries, suggesting that those countries have entered the 
'epidemiological transition'.80 
 
7.3 Risk factors for aSA H 
Paper II found that overweight (body mass index 25-29.9) participants were at lower risk of 
aSAH, compared to normal weight (body mass index 18.5-24.9) participants (HR 0.7, 95% 
CI: 0.4-1.0). The pathophysiological explanation for this is uncertain. Although the finding is 
supported by other studies,18, 23 the confidence intervals suggest a cautious interpretation. No 
overall association between total serum cholesterol, HDL cholesterol, triglycerides, body 
mass index, and the risk of aSAH were observed. 
Among participants <50 years of age, a statistically significant, inverse relationship 
between HDL cholesterol and the risk of aSAH was observed (HR 0.6, 95% CI: 0.4-0.9, 
adjusted for sex, age, smoking, and alcohol consumption). The biological explanation for an 
age-dependent relationship between HDL-cholesterol and the risk for aSAH is not clear.  
However, a strong, inverse association between HDL-cholesterol and the risk of coronary 
heart disease and ischemic stroke has been observed.81-85 This effect appears to be stronger in 
middle than in old age.84, 85 
protective effect of HDL-cholesterol on the risk of aSAH may be true, although it needs to be 
confirmed in future prospective studies. 
 
7.4 Aspects on the causes for the gender gap in aSA H 
 
7.4.1 Previous studies exploring causes for the gender gap in aSAH 
The causes for the disproportional incidence of aSAH in women have been sparsely 
investigated. The gender gap in aSAH is usually explained by systemic factors, including: i) 
hormonal and menstrual factors, and ii) intrinsic weakness of the female arterial wall.5, 19, 43, 44  
Studies have previously investigated menopause status, age at menarche, parity, use of 
oral contraceptives and hormone replacement therapy. The importance of menopause in the 
gender gap of aSAH is indirectly supported by the fact that the female preponderance of 
aSAH occurs between 45 and 55 years of age.5 Studies on the effect of menopause status on 
the risk for aSAH are however sparse. In a study by Longstreth at al of 103 women with 
aSAH and 206 age-matched controls, premenopausal women were at reduced risk for aSAH 
compared with age-matched postmenopausal women (OR 0.2, 95% CI: 0.1-0.7)45 The 
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Australasian Cooperative Research on Subarachnoid Hemorrhage) study of 286 women with 
aSAH and 286 age-matched controls found no significant difference in the risk for aSAH 
between pre- and postmenopausal women (OR 1.0, 95% CI: 0.6-1.6, adjusted for age).19 
The effect of age at menarche on the risk for aSAH is sparsely investigated. A study of 
124 cases and 248 controls did not find that early age at menarche (<13 years) were 
associated with increased risk for aSAH in parous women (OR 0.9, 95% CI: 0.7-3.2, adjusted 
for age, hypertension, and smoking).86 Similar findings were observed in the Australasian 
Cooperative Research on Subarachnoid Hemorrhage study.19 
Increased parity is possibly a protective factor for aSAH. Gaist et al, in a nested case-
control of 887 aSAH cases, found that the OR for aSAH declined with increasing parity (1 
child: reference; 2 children: OR=0.8, 95% CI: 0.7-1.0; 3 children: OR=0.7, 95% CI: 0.6-0.9; 4 
children: OR=0.7, 95% CI: 0.5-1.1; 5 children: OR=0.7, 95% CI: 0.3-1.4). The effect was 
reduced when adjusting for daily cigarette consumption before first childbirth.87 A protective 
effect of parity has also been reported with respect to the mortality of aSAH.88 The 
Australasian Cooperative Research on Subarachnoid Hemorrhage study however did not find 
that parous women had significantly reduced risk for aSAH (OR 0.9, 95% CI: 0.6-1.5) 
compared to nulliparous women.19 
No decisive effect of hormone replacement therapy and oral contraceptives on the risk 
for aSAH has been found. One prospective cohort has examined use of oral contraceptives 
and SAH mortality, but the number of SAH cases (n=7) was too small to draw a conclusion.89 
The Australasian Cooperative Research on Subarachnoid Hemorrhage study found no 
association between ever use of oral contraceptives and aSAH (OR 0.9, 95% CI: 0.5-1.5, 
adjusted for age).19 Similar findings were reported by Longstreth et al (OR 0.5, 95% CI: 0.3-
1.1, adjusted for age), and in the Collaborative Study on 
Cardiovascular Disease and Steroid Hormone Contraception (European population OR 1.6, 
95% CI: 0.9-2.8, unadjusted).45, 90 
female nurses, examined the use of hormone replacement therapy and the risk of aSAH. No 
association between current (RR 0.9, 95% CI: 0.6-1.3, adjusted for age) or past use (RR 0.9, 
95% CI: 0.6-1.3, adjusted for age) and the risk of aSAH was observed.91 The Australasian 
Cooperative Research on Subarachnoid Hemorrhage study found that ever use of hormone 
replacement therapy was associated with reduced risk for aSAH (OR 0.64, 95% CI: 0.41-
0.98), whereas Longstreth et al found that a reduced risk for aSAH with hormone replacement 
therapy was limited to those who had ever smoked.19, 45 
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The second theory for the gender gap, that intrinsic weakness of the arterial wall plays 
a role in promoting intracranial aneurysms in females, is motivated by the more frequent 
occurrence of multiple aneurysms in women than in men.43 However the theory remains to be 
proven. 
 
7.4.2 A new factor: sex differences in the vascular vulnerability to smoking 
Paper III found that current cigarette smoking was approximately twice as hazardous in 
women as in men (HR 6.5, 95% CI 3.56-11.9 vs HR 3.5, 95% CI 1.6-7.4). After adjusting for 
age, hypertension, and alcohol consumption, current cigarette smoking was 3.4 times more 
hazardous in female than male participants (HR 9.8, 95% CI 5.1-18.7 vs HR 2.9, 95% CI 1.3-
6.3). There were no statistically significant sex differences in HRs with respect to age, 
systolic blood pressure or alcohol consumption.  
To our knowledge, this is the first population-based cohort with case verification that 
demonstrates sex differences in risk factors for aSAH. Sex differences in risk factors for 
aSAH have previously been investigated in a meta-analysis17 of prospective studies.18, 25-34. 
This meta-analysis found hypertension and ever smoking more hazardous in women than 
men, but not current smoking or excessive alcohol consumption (>150 g per week). However, 
the meta-analysis included only three studies of men and women from the same population, of 
which two studies only examined alcohol consumption and not cigarette smoking,33, 34 and the 
third study consisted of cases identified using a national hospital discharge registry that were 
not validated.18 Retrospective case-control studies have reported conflicting results. One 
study found statistically significant higher risk of aSAH in male compared to female 
smokers,35 one study found statistically significant higher risk of aSAH in female compared 
to male smokers,36 whereas other studies found no statistically significant sex differences.18, 
37-40 
The finding of sex differences in cigarette smoking suggest that health interventions 
aimed at reducing the gender gap in aSAH should focus on reducing daily smoking in women 
at risk for aSAH. This appears to be supported by findings in the World Health 
 MONICA project, where an increased incidence of SAH in women was found 
only in populations where the prevalence of smoking was approximately evenly distributed in 
both sexes, whereas no sex difference in incidence or a male preponderance was found in 
populations where relatively fewer women smoked.92, 93 A similar difference in susceptibility 
to the harmful effects of smoking have been noted between ethnic groups, which may help to 
explain the differences in incidence of aSAH between ethnic groups.94, 95 
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Although the pathogenesis of intracranial aneurysms is not fully understood, a major 
theory is that aneurysm formation is initiated through an inflammatory response following 
endothelial injury. Jamous et al induced intracranial aneurysms in rats through renal 
hypertension and common carotid artery ligation, and found that intracranial aneurysm 
formation starts through endothelial injury, leading to the formation of an inflammatory zone, 
followed by a partial tear or defect in the inflammatory zone.96 Expansion of this defect forms 
the nidus of the intracranial aneurysm. Hemodynamic stress is considered an important 
contributor to the initial endothelial injury, as aneurysms usually arise where arteries are 
exposed to the maximum wall shear stress 51, 52. Studies have found that abnormal wall shear 
stress alters the balance of endothelial cell derived mediators involved in the regulation of 
vascular tone, hemostasis, vascular cell growth, and matrix production.97 Hemodynamic 
forces are considered a factor contributing to focal degeneration of the internal elastic lamina 
and subsequent aneurysm development.54 
The mechanisms of how cigarette smoking augments the formation of intracranial 
aneurysms are not well understood. However, smoking affects both hemodynamic forces and 
tissue inflammation. Smoking augments hemodynamic forces through vessel diameter and 
blood viscosity. Nicotine activates the sympathetic nervous system, with subsequent 
vasoconstriction and increased pulse rate.98 Compared to non-smokers, smokers have 
reversible increases in blood viscosity, due to increased hematocrit and plasma fibrinogen 
levels.99-101 The subsequent effect on hemodynamic forces has recently been demonstrated 
through computational fluid dynamics simulations.102 The effect of smoking on tissue 
inflammation may be mediated by direct effect of tobacco combustion products on the vessel 
wall or through increased blood concentration of white blood cells and increased monocyte-
endothelial cell adhesion.103-105 One might speculate that sex differences may be augmented 
by hormonal factors and the physiological changes the female vasculature undergo during 
menarche, pregnancy, and menopause.106 However, Paper III did not find that age at 
menarche, parity, menopause status or the use of hormone replacement therapy were 
significant risk predictors of aSAH in women or influenced the effect of smoking on the risk 
of aSAH in women. 
The risk for aSAH is increased in relatives of patients with aSAH.107 Further, a gene-
environment interaction with smoking for aSAH has been suggested. A case-control study of 
339 aSAH cases and 1,016 matched controls found that compared to non-smokers, the odds 
ratio (OR) for current smokers without a family history of aSAH was 3.1 (95% CI: 2.2-4.4), 
and for current smokers with a family history of aSAH 6.4 (3.1-13.2).108 The present thesis 
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did not find that a family history of stroke (hemorrhagic and ischemic) influenced the 
differential effect of smoking on the risk of aSAH in women and men. One might also 
speculate whether there are differences in risk factors according to the site of intracranial 
aneurysms, although this has not been proven.109, 110 
 
7.4.3 A new hypothesis: local sex differences in the intracranial arteries? 
Paper IV explores a new hypothesis for the gender gap in aSAH: local sex differences in the 
hemodynamic forces acting upon the wall of the different intracranial arteries. The hypothesis 
is motivated by the empirical observation that sex differences in the frequency of intracranial 
aneurysms vary with the different intracranial arteries. In a study by Horiuchi et al of 2577 
patients treated surgically for aSAH, the female-to-male ratio of ruptured intracranial 
aneurysms varied from 1.1:1 for the anterior cerebral artery, 2.1:1 for the internal carotid 
artery, 1.5:1 for the middle cerebral artery, and 1.3:1 for the basilar artery.48 Similar findings 
have been reported by other studies.43, 49, 50 This uneven sex distribution suggests that a 
physiologic factor may be involved  a local sex difference in the different intracranial 
arteries and not only systemic sex differences. 
Paper IV found that the diameter of the middle cerebral and carotid artery was smaller 
in females than males. The average diameters were used to create idealized, averaged 
bifurcations of the middle cerebral and internal carotid artery for females and males. 
Computational fluid dynamics simulations revealed higher wall shear stress in the female 
middle cerebral (19%) and internal carotid (50%) artery bifurcations compared with the male 
bifurcations. The findings of Paper IV, that the female arterial wall is exposed to higher 
hemodynamic forces than the male arterial wall, is caused by females having smaller 
intracranial arteries and increased blood flow velocity compared with males. Given a constant 
mass flow, a smaller vessel diameter causes increased blood flow velocity and higher wall 
shear stress. Sex differences in wall shear stress at the apex of the bifurcation are likely 
caused by sex asymmetries in the diameters of the parent vessels and branches. The small 
sample size in Paper IV precluded statistical analyses of this. However, the computational 
models assessed all factors caused by differences in the vessel diameters of females and 
males. The simulations showed that the sum of all sex differences in the vessel diameters 
caused higher wall shear stress at the apex of the female intracranial bifurcation. It is possible 
that sex differences in bifurcation geometry and blood flow velocity, causing higher shear 
forces in female intracranial artery bifurcations, over decades may result in more aneurysms 
in females than in males. This may be augmented by the physiologic changes the female 
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cardiovascular system undergoes during menopause, such as spontaneous increase in 
proinflammatory molecules,111 increased vascular constrictor factors and myointimal 
hyperplasia, as well as decreased plasma volume and cardiac output.112 
 
7.5 Directions for future research 
Knowledge about the incidence and risk factors for aSAH is important for public health 
planning, education, and identifying patients with increased risk for the disease.  The internal 
validity of incidence studies based on hospital discharge registries without person identifiers 
is limited due to possible measurement errors. Future studies should therefore be conducted 
using validated, person identifiable registries. The political decision in 2007 to include 
person-identified medical data in the Norwegian Patient Register, and in 2010 to establish a 
Norwegian registry of cardiovascular diseases will enable this in the future. 
Knowledge about the etiological factors that cause the female preponderance of aSAH 
is important as it might give valuable insight into the pathogenesis of aSAH, and if reversible 
causes are found, health interventions may reduce the burden of aSAH in women. The present 
thesis suggests a health intervention program focused on reducing daily smoking in women at 
risk for aSAH. Future research might evaluate such health intervention, although the low 
incidence of aSAH would require a large number of participants.  
The effect of body mass index, hormonal and reproductive factors should be further 
addressed in a population-based cohort study. The fact that the sex differences in the 
prevalence of aSAH are not constant, but vary with the intracranial arteries should lead to 
examinations of potential sex differences in the different intracranial arteries. The hypothesis 
put forward in Paper IV, that sex differences in the anatomy of the intracranial arteries 
contribute to the female preponderance of intracranial aneurysms, should be examined in a 
properly statistically powered, prospective trial using advanced radiological imaging of the 
intracranial vasculature in healthy volunteers. This information may be available from for 
instance the third survey of the HUNT study (performed between 2006 and 2008), which 
included cerebral magnetic resonance angiography of healthy volunteers. Further, differences 
in risk factors for aSAH according to the site of intracranial aneurysms, adjusted for age and 
sex, should be investigated as this may yield knowledge on the etiology of aneurysm 
formation. 
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8 C O N C L USI O NS 
 
Incidence of aSAH in Norway decreased from 1999 to 2007, with significant regional 
variations indicating an increasing gradient from south to north. 
 
Overweight (body mass index 25.0-29.9) was inversely associated with the risk of aSAH, 
compared to normal weight (body mass index 18.5-24.9). No overall association between 
HDL, LDL, total serum cholesterol, triglycerides, and the risk for aSAH was observed. 
  
Current cigarette smoking is a stronger risk factor for aSAH in women than in men, compared 
to never smoking. No statistically significant sex differences with respect to systolic blood 
pressure and alcohol consumption were observed. 
 
Sex differences in arterial size and blood flow velocity result in higher hemodynamic forces 
acting upon the female arterial wall. This is a new hypothesis that may partially explain why 
intracranial aneurysms and SAH are more likely to occur in females than males.  
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